Signal bias, allosterism, and polymorphic variation at the GLP-1R: Implications for drug discovery
Semaglutide and Tirzepatide Semaglutide is primarily a GLP-1 receptor agonist Tirzepatide targets GLP-1 and GIP receptors Retatrutide targets GLP-1, GIP, and glucagon receptor pathways Because retatrutide activates additional metabolic receptors, some studies suggest that retatrutide may deliver greater weight loss compared with semaglutide and tirzepatide
In case further glycemic control is still needed, the dose can be augmented to 1.8 mg daily
It has therefore been postulated that the administration of molecules capable of mimicking the action of GLP-1 and/or GIP could reproduce this incretin effect and thus stimulate insulin production and improve glycemic control in type 2 diabetics
"Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction"
Maintenance and Adjustments: After reaching your target weight, your program may be adjusted for maintenance to ensure you continue to optimize your weight loss journey
